IRB #

STUDY00019380

Title

An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate

Principal Investigator

Lara Davis

Study Purpose

The purpose of this study is to understand if scheduled glucarpidase reduces the levels of methotrexate in patients’ blood and lead to shorter hospitalizations and a reduction in toxicities.

Medical Condition(s)

osteosarcoma, glucarpidase

Eligibility Criteria

25 years or older with osteosarcoma

Recommended treatment includes methotrexate

Age Range

25 - 100

Healthy Volunteers Needed

No

Duration of Participation

10 weeks of treatment, then 30 days of follow-up time.

Minors Included

No

Contact

Knight Clinical Trials Office
trials@ohsu.edu

Sponsor

Recruitment End

09/30/2020

Compensation Provided

No


Go Back